| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Thursday’s Close |
|---|---|---|---|---|---|
| NVS | Novartis AG | $85.13 | $197.65B | N/A |
Better Buy: Philip Morris International Inc. vs. Anheuser-Busch InBev NV
https://www.fool.com/investing/2017/08/31/better-buy-philip-morris-international-inc-vs-anhe.aspx?source=iedfolrf0000001
Aug 31, 2017 - In a battle of sin stocks, we've got a draw. But each one's strength lies in a different area.
4
3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma
https://www.fool.com/investing/2017/08/28/3-reasons-to-applaud-gilead-sciences-acquisition-o.aspx?source=iedfolrf0000001
Aug 28, 2017 - There's a lot to like with Gilead's buyout of cell therapy leader Kite Pharma.
4
Why Are Cancer Drugs So Expensive?
https://www.fool.com/investing/2017/09/20/why-are-cancer-drugs-so-expensive.aspx?source=iedfolrf0000001
Sep 20, 2017 - If it seems like oncology drug prices are rapidly outpacing inflation, it’s because they are.
4
Teva Investors Get Headache Relief
https://www.wsj.com/articles/teva-investors-get-headache-relief-1537200489?mod=rss_Technology
Sep 17, 2018 - A new migraine drug is a big win amid the turnaround of generics business.
4
Why the Ionis Spinoff Will Be a Win for Long-Term Investors
https://www.fool.com/investing/2017/04/18/why-the-ionis-spinoff-will-be-a-win-for-long-term.aspx?source=iedfolrf0000001
Apr 18, 2017 - Ionis keeps doing what it's good at: developing new drugs and setting up future revenue streams
4
Why Trivago NV Stock Plummeted Wednesday
https://www.fool.com/investing/2017/09/06/why-trivago-nv-stock-plummeted-wednesday.aspx?source=iedfolrf0000001
Sep 06, 2017 - Trivago surprised investors this week when it lowered its outlook for 2017. Here are the details.
3
Why You're Smart to Buy Vertex Pharmaceuticals Stock
https://www.fool.com/investing/2017/07/15/why-youre-smart-to-buy-vertex-pharmaceuticals-stoc.aspx?source=iedfolrf0000001
Jul 15, 2017 - Forget the sky-high valuation. Vertex Pharmaceuticals stock is a smart pick.
3
Is the System Rigged Against Biosimilars?
https://www.fool.com/investing/2017/08/26/is-the-system-rigged-against-biosimilars.aspx?source=iedfolrf0000001
Aug 26, 2017 - Pfizer and Amgen are encountering problems getting traction for their biosimilars. Is the system rigged against them?
2
Why Juno Therapeutics Shares Vaulted 46% Higher in August
https://www.fool.com/investing/2017/09/05/why-juno-therapeutics-shares-vaulted-46-higher-in.aspx?source=iedfolrf0000001
Sep 05, 2017 - Optimism is soaring following the FDA approval of Novartis' CAR-T and the $11.9 billion acquisition of CAR-T developer Kite Pharma.
2
Stocks making the biggest move premarket: UTX, AAPL, HIBB, NVS, TSLA & more
https://www.cnbc.com/2018/11/27/stocks-making-the-biggest-move-premarket-utx-aapl-hibb-nvs-tsla--more.html
Nov 27, 2018 - Names on the move ahead of the open.
2